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Given the importance of costimulation in T cell re-1Julia McFarlane Diabetes Research Centre
sponses, it is generally believed that the effectivenessUniversity of Calgary
of CD154 blockade in these pathological processes isFaculty of Medicine
mediated by passive interference with CD40 signaling3330 Hospital Drive N.W.
(Grewal and Flavell, 1998).Calgary, Alberta
Regulatory CD4CD25 cells are a unique lymphocyteCanada T2N 4N1
subset that comprises 5%–10% of all CD4 T cells. The2 Second Department of Internal Medicine
major hallmarks of this T cell subpopulation are that itGunma University School of Medicine
does not proliferate in response to TCR ligation in vitro,Gunma 371
that it constitutively expresses the CD25 and CTLA-4Japan
markers, and that it suppresses the activation of effector
CD4 and CD8 cells by their cognate antigens, but in
an antigen nonspecific manner (Sakaguchi, 2000; SinghSummary
et al., 2001). Although little is known about the mecha-
nisms that control the development and/or function ofWe report that disruption of CD154 in nonobese dia-
CD4CD25 cells, studies in CD28-deficient NOD micebetic (NOD) mice abrogates the helper function of
and CD40-deficient BALB/c mice have suggested thatCD4CD25 T cells without impairing the regulatory
their development requires B7-CD28 and CD40-CD154activity of CD4CD25 T cells. Whereas CD4 T cells
interactions (Kumanogoh et al., 2001; Salomon et al.,from NOD mice enhanced a diabetogenic CD8 T cell
2000). Ligation of surface molecules such as CTLA-4,response in monoclonal TCR-transgenic NOD mice,
TRANCE, or GITR, as well as secretion of antiinflamma-CD4 T cells from NOD.CD154/ mice actively sup-
tory cytokines like TGF-, IL-4, and IL-10, have all beenpressed it. Suppression was mediated by regulatory
implicated in the regulation or mediation of the sup-CD4CD25 T cells capable of inhibiting CD8 T cell
pressive activity of CD4CD25 cells (Asseman et al.,responses induced by peptide-pulsed dendritic cells
1999; Green et al., 2002; McHugh et al., 2002; Powrie(DCs), but not peptide/MHC monomers. It involved in-
et al., 1996; Read et al., 2000; Shevach et al., 2001;hibition of DC maturation, did not occur in the pres-
Shimizu et al., 2002). The fact that the regulatory activityence of CD154 T-helper cells, and could be inhibited
of CD4CD25 cells requires TCR signaling has alsoby activation of DCs with LPS, CpG DNA, or an agonis-
led to the idea that their activation requires cognatetic anti-CD40 mAb. Thus, in at least some genetic
interactions with DCs, at least in vivo (Cederbom etbackgrounds, CD154-CD40 interactions and innate
al., 2000; Shevach et al., 2001; Thornton and Shevach,stimuli release immature DCs from suppression by
1998). However, since CD4CD25 cells can suppressCD4CD25 T cells.
T cell responses in vitro in the absence of APCs, it has
also been proposed that APCs are not the target of theirIntroduction
regulatory activity (Thornton and Shevach, 1998).
Development of autoimmune diabetes in nonobeseThe interaction between CD40 on professional antigen-
diabetic (NOD) mice is the result of a complex CD4 and
presenting cells (APCs) and CD154 on CD4 Th cells
CD8T cell-dependent autoimmune process against the
plays a critical role in the generation of cytotoxic
pancreatic  cells. Although CD8 T cells play critical
T-lymphocyte (CTL) responses. Ligation of CD40 on roles in the initiation and progression of diabetes, they
dendritic cells (DCs), for example, upregulates the ex- require the assistance of CD4 Th-cells to do so (Liblau
pression of costimulatory molecules and elicits the pro- et al., 2002). To investigate whether CD4/CD8 T cell
duction of proinflammatory cytokines (Grewal and Fla- collaboration in diabetes requires CD40-CD154 interac-
vell, 1998). These changes endow DCs with the ability tions, we followed the fate of a representative, highly
to costimulate antigen-specific CD8 and CD4 T cell diabetogenic, TCR-transgenic CD8 T cell specificity
responses, and to foster CD8 T cell differentiation into (8.3) (Verdaguer et al., 1997) in the absence or presence
CTL (Bennett et al., 1998; Ridge et al., 1998; Schoen- of CD154-deficient CD4 T cells. We found that the
berger et al., 1998). As a result, CD154 blockade inhibits CD154 deficiency had no effect on the diabetogenic
the generation of T cell responses against viruses and activity of 8.3-CD8 cells in recombination-activating
exogenous antigens, and prevents the development of gene (RAG-2)-deficient, TCR-transgenic mice (lacking
endogenous CD4 T cells). Surprisingly, however, this
*Correspondence: psantama@ucalgary.ca. deficiency completely prevented the onset of disease in
3 These authors contributed equally to this work. RAG-2-competent TCR-transgenic mice, which export
4 Present address: Service of Immunology, Centre de Recherche
endogenous CD154-deficient CD4 cells to the periph-Clinique, Universite´ de Sherbrooke, 3001, 12 Avenue N., Sherbrooke,
ery. Unlike their CD154-competent counterparts, theQuebec J1H 5N4, Canada.
CD154-deficient CD4 cells of these mice actively sup-5 Present address: Immunology Unit, Hospital Universitari Germans
Trias i Pujol, Carretera del Canyet s/n, Badalona, Barcelona, Spain. pressed the diabetogenic activity of 8.3-CD8 cells. This
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suppressive activity was mediated by CD4CD25 cells diabetes could not be accounted for by abnormal devel-
opment or function of the transgenic CD8 cells. Todisplaying a typical regulatory phenotype but unexpected
target cell specificity. Importantly, these CD4CD25 ascertain whether these cells could also respond spon-
taneously to antigen in vivo, we followed the kinetics ofcells inhibited DC maturation in vitro and in vivo and
suppressed 8.3-CD8 T cell responses induced by non- diabetes in 8.3-NOD.RAG-2/CD154/ mice expressing
a rat insulin promoter (RIP)-driven B7.1 transgene in activated DCs, but not responses induced by activated
DCs or peptide/MHC monomers. This inhibitory effect cells. RIP-B7.1-transgenic  cells are superior to wild-
type  cells at inducing 8.3-CD8 activation becauserequired CTLA-4, but not IL-4, IL-10, or TGF-1, and
could be prevented by treatment of the mice with acti- they possess costimulatory activity (Supplemental Fig-
ure S2). As expected, transgenic expression of B7.1 invated DCs, CpG DNA, or an agonistic anti-CD40 mAb.
Collectively, our data show that development of regula-  cells completely abrogated the diabetes resistance of
8.3-NOD.RAG-2/CD154/ mice (Figure 1F). Adoptivelytory CD4CD25 cells in NOD mice is independent of
CD154; that these cells inhibit certain T cell responses transferred NRP-A7-pulsed DCs also triggered diabetes
in 8.3-NOD.RAG-2/CD154/ mice (Table 1, Groups 19by suppressing DC maturation; and that activation of
DCs by innate stimuli or CD4 Th cells renders them versus 18 or 20), further supporting the idea that the
8.3-CD8 cells maturing in these mice are antigen re-resistant to suppression by regulatory T cells. We con-
clude that, in at least some genetic backgrounds, the sponsive.
CD154-CD40 interaction controls the balance between
helper and regulatory T cells in immune responses. 8.3-CD8 Cells Maturing in the Presence
of CD154/CD4 Cells Do Not Respond
to CD4 T Cell HelpResults
CD4 Th cells promote CD8 responses by eliciting co-
stimulatory activity on APCs. Thus, we asked whether8.3-CD8 Cells Maturing in the Presence of
CD154/CD4 Cells Are Not Diabetogenic exogenous CD154CD4 cells could restore the respon-
siveness of naive 8.3-CD8 cells from 8.3-NOD.RAG-8.3-NOD.RAG-2/ mice, which bear a monoclonal TCR
repertoire, develop diabetes with the same incidence 2/CD154/ mice to endogenous, autoantigen-loaded
APCs (i.e., pancreatic lymph node DCs). Whereas CD4and tempo as 8.3-NOD.RAG-2//CD154/ mice, indi-
cating that 8.3-CD8 cells do not need to express CD154 splenocytes from prediabetic NOD mice significantly in-
creased the incidence of diabetes in CD154-competentto differentiate into CTL (Table 1, Groups 1 versus 4)
(Amrani et al., 2002). Although naive 8.3-CD8 cells can and CD154-deficient 8.3-NOD.RAG-2/ mice (Table 1,
Groups 1 versus 2, or 4 versus 5), they were unable totrigger diabetes in the absence of CD4 T cells, they
are more diabetogenic in their presence (Verdaguer et overcome the diabetes resistance of CD154-deficient
8.3-NOD.RAG-2 mice (Table 1, Groups 21 versus 18).al., 1997). As a result, 8.3-NOD.RAG-2/CD154 mice,
which bear both TCR-transgenic CD8 cells and CD4 These results suggested that 8.3-CD8 cells maturing
in the presence of CD154/CD4 cells are refractory tocells expressing endogenous TCRs, develop diabetes
more frequently and earlier than 8.3-NOD.RAG-2// T cell help.
CD154 mice (Verdaguer et al., 1997). Likewise, transfer
of CD4 splenocytes from wild-type NOD mice into 8.3- DCs and Macrophages from NOD.CD154/ Mice
NOD.RAG-2/ or 8.3-NOD.RAG-2//CD154/ hosts in- Are Hypoimmunogenic
creases the incidence of diabetes (Amrani et al., 2002; The ability of B7.1-transgenic cells and peptide-pulsed
Verdaguer et al., 1997) (Table 1, Groups 1 versus 2 or 4 DCs to trigger diabetes in 8.3-NOD.RAG-2/CD154/
versus 5). To investigate whether CD4 Th cells en- mice, coupled with the inability of CD4 Th cells to
hanced the diabetogenic potential of 8.3-CD8 cells in do so, suggested that the endogenous APCs of these
a CD154-dependent fashion, we compared diabetes de- animals were hypoimmunogenic. To investigate this,
velopment in 8.3-NOD.RAG-2/CD154 versus 8.3- we compared the ability of CFSE-labeled 8.3-CD8
NOD.RAG-2/CD154/ mice (both capable of exporting cells from 8.3-NOD.RAG-2/CD154, 8.3.NOD.RAG-
CD4 T cells to the periphery). Surprisingly, 8.3- 2//CD154/, and 8.3.NOD.RAG-2/CD154/ mice to
NOD.RAG-2/CD154/ mice developed neither diabe- proliferate in the pancreatic (PLN) and mesenteric lymph
tes nor insulitis. This indicated that 8.3-CD8 cells ma- nodes (MLN) of NOD and NOD.CD154/ mice within 6
turing in the presence of CD154/CD4 cells were no days of transfer. 8.3-CD8 cells from all three types
longer diabetogenic (Figures 1A and 1B). of mice proliferated only in the PLNs of NOD, but not
NOD.CD154/ hosts (Figure 2A; data not shown). Al-
though the PLNs of NOD and NOD.CD154/ mice har-8.3-CD8 T Cells Maturing in the Presence of
CD154/CD4 T Cells Are Functionally Normal bor similar numbers of DCs (1.9  0.1 versus 1.8 
0.8 104, respectively), we cannot exclude the possibil-8.3-NOD.RAG-2/CD154/ mice displayed thymic and
splenic cytofluorometric profiles similar to those seen ity that they contain different numbers of autoantigen-
loaded DCs.in 8.3-NOD.RAG-2/CD154 mice (Supplemental Fig-
ure S1 at http://www.immunity.com/cgi/content/full/19/6/ In vitro experiments confirmed that, compared to
those from wild-type NOD mice, splenic and, especially,877/DC1). Furthermore, their splenic CD8 cells prolif-
erated vigorously, secreted high levels of IFN-, and PLN DCs of NOD.CD154/ mice were less efficient at
inducing proliferation and IFN- secretion by 8.3-CD8differentiated efficiently into CTL upon stimulation with
a target peptide (NRP-A7) in vitro (Figures 1C–1E). Thus, cells (Figure 2B; data not shown). In addition, the PLN
DCs of NOD.CD154/ mice expressed lower levels ofthe resistance of 8.3-NOD.RAG-2/CD154/ mice to
DCs as Targets of Regulatory T Cells
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Figure 1. Diabetogenicity and Function of 8.3-CD8 Cells in the Presence of CD154/CD4 Cells
(A) Incidence of diabetes in female 8.3-NOD.RAG-2/CD154 (n  214) versus 8.3-NOD.RAG-2/CD154/ mice (n  59; P  0.0001), and 8.3-
NOD.RAG-2//CD154 (n  106) versus 8.3-NOD.RAG-2//CD154/ mice (n  63).
(B) Insulitis scores of 8.3-NOD-RAG-2/CD154 (n  4; 6 weeks) versus 8.3-NOD.RAG-2/CD154/ mice (11 10- to 11-week-old plus 6 20-
to 31-week-old; no differences in insulitis scores were observed between the two age groups) (P  0.0001).
(C) Proliferation of splenic CD8 cells against NRP-A7-pulsed (1 	M) NOD DCs. Background responses (against TUM, 1 	M) were subtracted.
(D) Secretion of IFN- by 8.3-CD8 cells against peptide-pulsed DCs.
(E) Cytotoxicity of NRP-A7-differentiated 8.3-CD8 cells against NRP-A7- or TUM-pulsed RMA-SKd cells (1 	M) at a 1:10 target:effector ratio.
(F) Incidence of diabetes in 8.3/RIP-B7.1-NOD.RAG-2/CD154/ (n  17) and 8.3/RIP-B7.1-NOD.RAG-2/CD154 mice (n  8). Bars in (B)–(E)
show the standard error of the means.
several DC markers, including B7.1, CD11c, and CD40 DC1). Not all APCs were affected, however, as splenic B
cells from NOD.CD154/ and NOD mice presented NRP-(Figure 2C). These interstrain differences in the pheno-
type and APC activity of DCs were not seen with bone A7 with similar efficiency (Supplemental Figure S3).
Experiments comparing the APC activity of PLN DCsmarrow-derived DCs (Figure 2B; data not shown), indi-
cating that they were acquired, rather than genetic. Nev- from NOD.CD154/ and B10.H2g7 mice (both strains be-
ing insulitis free) indicated that the hypofunctional activ-ertheless, they were not unique to DCs, because perito-
neal macrophages from NOD.CD154/ mice were also ity of NOD.CD154/ DCs was not secondary to absence
of local inflammation (as a source of DC stimuli) (Figureunable to activate 8.3-CD8 cells (Supplemental Figure
S3 at http://www.immunity.com/cgi/content/full/19/6/877/ 2D). PLN tissue is virtually absent in NOD.scid and
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Figure 2. Function and Phenotype of DCs in NOD.CD154/ Mice
(A) Proliferation of naive, CFSE-labeled 8.3-CD8 cells in the PLNs and MLNs of NOD or NOD.CD154/ mice (8 to 12 weeks old) 6 days
after transfer.
(B) Proliferation of naive 8.3-CD8 cells against peptide-pulsed (1 	M) splenic or PLN DCs (5  103) or immature bone marrow-derived DCs
(104) (8- to 13-week-old donors).
(C) Downregulation of DC markers on PLN DCs of NOD.CD154/ versus NOD mice. DCs were purified from PLN cells pooled from several
mice (20 weeks old). Mfi, mean fluorescence intensity.
(D) IFN- secretion by naive 8.3-CD8 cells against splenic or PLN-derived DCs (5  103; peptide-pulsed) (20-week-old donors).
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NOD.RAG-2/ mice. This precluded a comparison of NOD mice up to 10 weeks of age (Figure 3A). Further-
more, unlike their CD4CD25 counterparts, preactivatedthe functional activity of PLN DCs from NOD.CD154/
CD4CD25cells from both NOD and NOD.CD154/micemice versus mice lacking T cells as a source of DC
could inhibit the ability of naive 8.3-CD8 cells to pro-stimuli. However, studies with the splenic DCs of these
duce IFN- in response to NRP-A7-pulsed DCs over amice indicated that the hypoimmunogenic activity of
range of DC densities (Figure 3B) and CD4:CD8 T cellNOD.CD154/DCs was not due to absence of functional
ratios (Figure 3C). This inhibitory activity was also seen(CD154-competent) Th cells (Figure 2D). Thus, the
when naive CD4CD25 cells were activated within theCD154 deficiency somehow causes DC (and macro-
assay, either by DCs coated with a suboptimal concen-phage) hypofunction in vivo.
tration of anti-CD3 mAb (unable to elicit the activation
of 8.3-CD8 cells) or by allogeneic DCs (Supplemen-
tal Figures S4 at http://www.immunity.com/cgi/content/CpG DNA Restores the Responsiveness of APCs
full/19/6/877/DC1). Furthermore, it was not a peculiarityfrom NOD.CD154/ Mice to CD4 Th Cells
of NRP-A7, because it was also seen with DCs pulsedWe next asked whether activation of the hypofunctional
with the natural ligand of 8.3-CD8 cells (IGRP206-214)APCs of 8.3-NOD.RAG-2/CD154/ mice with CpG DNA
(Lieberman et al., 2003) (Supplemental Figure S5A).could initiate diabetogenesis in these animals. CpG DNA
Assays employing LCMV-specific TCR-transgenic CD8can enhance CTL responses by ligating Toll-like recep-
cells as responders and LCMV gp33 peptide-pulsedtor (TLR)-9 on DCs (Hemmi et al., 2000). CpG DNA had no
DCs as stimuli further indicated that such suppressivestatistically significant effect in overcoming the ignorant
activity was not specific for autoreactive CD8 T cellstate in 8.3-NOD.RAG-2/CD154/ mice (Table 1, Groups
responses (Supplemental Figure S5B).23 versus 18). However, it restored the responsiveness
We next tested whether CD4CD25 cells from NODof their APCs to exogenous CD154 CD4 Th cells,
and NOD.CD154/ mice also had regulatory activity inresulting in diabetes (Table 1, Groups 22 versus 21). In
vivo. We first compared the ability of CD154/ CD4these experiments, diabetes was caused by 8.3-CD8
CD25 and CD154/ CD4 CD25 cells to inhibit diabe-cells because none of the 6 NOD.RAG-2//CD154/
togenesis in 8.3-NOD.RAG-2//CD154/mice. The inci-mice that were treated with CpG DNA and CD154CD4
dence of diabetes in mice that received CD154/cells developed diabetes (Table 1, Groups 17 versus
CD4CD25 cells was similar to that of untreated con-
22). Therefore, activation of the hypoimmunogenic APCs
trols (Table 1, Groups 7 and 4), and significantly lower
of 8.3-NOD.RAG-2/CD154/ mice with CpG DNA re-
than that of mice treated with CD154 CD4 cells (Table
stored their ability to mount a diabetogenic 8.3-CD8
1, Groups 7 and 5). This indicated that, unlike total CD4
response with the assistance of CD4 Th cells. cells from NOD.CD154/ and NOD mice (with sup-
pressive and helper activity, respectively), CD4 CD25
cells from NOD.CD154/ mice could neither inhibit nor
CD154/CD4 Cells Suppress the Diabetogenic promote 8.3-CD8-induced diabetes. In contrast, none
Activity of 8.3-CD8 Cells of seven 8.3-NOD.RAG-2//CD154/ mice that re-
CD4 T cell-deficient 8.3-NOD.RAG-2//CD154/ and ceived CD154/ CD4 CD25 cells developed diabetes
8.3-NOD.RAG-2//CD154 mice develop diabetes with (Table 1, Groups 8 versus 4). This indicated that the
the same incidence (Figure 1A). Hence, we reasoned antidiabetogenic activity of CD154/ CD4 cells resided
that the APC hypofunction and diabetes resistance of in the CD4CD25 subset. Similar results were obtained
8.3-NOD.RAG-2/CD154/ mice might be caused by in mice transfused with CD154 CD4 CD25 cells (Ta-
CD154/ CD4 cells. To investigate this, we monitored ble 1, Groups 9 versus 8), showing that expression of
diabetes development in 8.3-NOD.RAG-2//CD154/ CD154 on the CD4 CD25 cells themselves does not
mice transfused with splenic CD4 cells from NOD or inhibit their regulatory activity.
NOD.CD154/ mice. Mice transfused with CD154
CD4 cells developed an increased incidence of diabe- CD4 CD25 Cells from NOD and NOD.CD154/
tes compared to nontransfused controls (Table 1, Mice Are Phenotypically Similar
Groups 5 versus 4). In contrast, mice transfused with We next investigated whether CD4CD25 cells from
CD154/ CD4 cells developed a significantly lower in- NOD and NOD.CD154/ mice shared the hallmarks of
cidence of diabetes (Table 1, Groups 6 versus 4). As conventional (BALB/c) regulatory CD4CD25 cells
expected, CD154CD4 cells did not trigger diabetes (McHugh et al., 2002; Nakamura et al., 2001; Sakaguchi,
in non-TCR-transgenic NOD.RAG-2/ hosts (Table 1, 2000; Shimizu et al., 2002). Unlike CD4CD25 cells,
Group 3). Therefore, whereas CD154CD4 cells po- CD4CD25 cells from both types of mice expressed
tentiate the diabetogenic activity of 8.3-CD8 cells, CD103, CD134, GITR, CTLA-4, and surface TGF-1. No
CD154/CD4 cells actively suppress it. obvious differences were noted in the phenotype of
CD4CD25 cells isolated from spleen, MLNs, or PLNs
(Supplemental Figure S6, and data not shown). These
The Antidiabetogenic Activity of CD154/ CD4 cells proliferated poorly in response to anti-CD3 (Figure
Cells Is Mediated by CD4CD25 Cells 4A), but addition of rIL-2 to the cultures restored respon-
We wondered whether the suppressive activity of siveness, indicating that they were anergic, as expected
CD154/CD4 cells might be mediated by the CD4 (Figure 4A). The CD4CD25 cells from both NOD and
CD25 subset. Flow cytometric studies showed that NOD.CD154/ mice proliferated slightly in response to
nontransgenic NOD.CD154/ mice harbor as many rIL-2 in the absence of anti-CD3, and this response was
enhanced by anti-GITR antibodies (Figure 4B), as de-CD4CD25 cells in the thymus and MLNs as wild-type
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Figure 3. NOD.CD154/ Mice Export Functional CD4CD25 Cells to the Periphery
(A) Percentage of CD4 cells that are CD25 in the thymus, MLN, and PLN of NOD (thymus, spleen, and MLN: n  4; PLN: n  8) and
NOD.CD154/ mice (n  5) (age of PLN NOD and NOD.CD154/ donors: 11  2 and 13  3 weeks, respectively). *, P0.007.
(B) Activated CD4CD25, but not CD4CD25 cells from NOD.CD154/ mice (2  105) inhibit IFN- secretion by naive 8.3-CD8 cells (2 
104) in response to NRP-A7 peptide-pulsed DCs (1 	M) over a range of DC numbers.
(C) Activated CD4CD25 but not CD4CD25 cells (0–2  105) inhibit 8.3-CD8 cell responses (2  104) to NRP-A7-pulsed DCs (104) over a
range of CD8:CD4 ratios. In (B) and (C), background responses to the control peptide TUM were subtracted. DCs were generated from
bone marrow and plated as immature cells. CD4CD25 cells were purified from pooled MLNs and spleen.
scribed for BALB/c CD4CD25 cells (McHugh et al., cells via direct cell-to-cell interactions (Thornton and
Shevach, 1998). However, our in vivo studies suggested2002; Shimizu et al., 2002). The cytokine profiles of
the inability of 8.3-CD8 cells to trigger diabetes in 8.3-splenic and MLN CD4CD25 cells from these two types
NOD.RAG-2/CD154/ mice was due to impaired T cellof mice were also similar to those described for regula-
activation (as a result of DC hypofunction), rather thantory T cells isolated from other strains (McHugh et al.,
to direct T cell suppression. In agreement with this idea,2002; Roncarolo and Levings, 2000). CD3 crosslinking
CD4CD25 cells from both NOD and NOD.CD154/induced the secretion of high levels of IL-10 and some
mice were unable to inhibit 8.3-CD8 responses inducedIL-4 (but very little IFN-and no IL-2 or TGF-), particularly
by NRP-A7/Kd monomers, over a wide range of concen-in the presence of rIL-2 (Figure 4C; data not shown).
trations (Figure 5A). Similar results were obtained withCD4CD25 cells isolated from the PLNs were also aner-
IGRP206-214/Kd monomers, which have lower agonistic ac-gic, and produced IL-10 but very little or no IFN-, in
tivity than NRP-A7/Kd monomers (Figure 5A). Althoughresponse to anti-CD3 (not shown). Thus, the
the mechanisms responsible for the increased produc-CD4CD25 cells maturing in NOD and NOD.CD154/
tion of IFN- by 8.3-CD8 cells in the presence versusmice are phenotypically similar to those described in
absence of CD4CD25 cells are unclear (Figure 5A),other models. We conclude that development of these
these results suggested that CD4CD25 cells fromcells in the NOD background does not require CD154-
NOD and NOD.CD154/ mice cannot directly inhibit 8.3-CD40 interactions.
CD8 cells in vitro.
We next asked whether CD4CD25 cells could alter
Suppression of DC Maturation by CD4CD25 Cells the phenotype and function of DCs in vitro. Initial experi-
It has been shown that BALB/c CD4CD25 cells sup- ments indicated that immature bone marrow-derived
DCs cultured for a relatively short period of time (56 hr)press the proliferative activity of syngeneic CD4CD25
Immunity
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Figure 4. Function of CD4CD25 Cells from NOD and NOD.CD154/ Mice
(A) Splenic/MLN CD4CD25 cells (105; from 13- to 16-week-old mice) do not proliferate in response to anti-CD3-coated beads (105) in the
absence of rIL-2.
(B) Splenic/MLN CD4CD25 cells (from 13- to 16-week-old mice) proliferate moderately in response to rIL-2 in the presence of irradiated
NOD splenocytes (105), and this response is enhanced by anti-GITR Abs.
(C) Cytokine profiles of splenic/MLN CD4CD25 and CD4CD25 cells. Freshly isolated cells (105) were stimulated with anti-CD3-coated
beads (105) in the absence (upper panels) or presence of rIL-2 (lower panels). Supernatants collected at 48 hr were assayed for various cytokines.
with activated NOD CD4CD25 cells expressed lower type of activated DCs cultured in the presence of
CD154 or CD154/ CD4CD25 cells was similar tolevels of B7.1, B7.2, CD11c, CD40, and I-Ag7 than DCs
cultured with activated CD4CD25 cells (Figure 5B). that of activated DCs cultured alone (Figure 5D, left and
middle panels; data not shown). This suggested thatTo ascertain whether regulatory T cells actually inhibited
DC maturation, we compared the phenotype of imma- mature DCs are refractory to the suppressive activity of
regulatory T cells. In agreement with this, CD4CD25ture, bone marrow-derived DCs (after a 7–10 day culture
of marrow in GM-CSF and IL-4), with that of the same cells could not inhibit the secretion of IFN- by 8.3-CD8
cells in response to CpG- or LPS-activated, NRP-A7-DCs subsequently cultured alone or in the presence of
CD154/ CD4CD25 or CD154/ CD4CD25 cells for pulsed DCs (Figure 5E). Conversely, CpG DNA, which
binds to TLR9 on DCs but not CD4CD25 cells, could56 hr. Immature DCs and DCs exposed to CD4CD25
cells expressed similarly low levels of B7.1, B7.2, CD11c, not upregulate markers such as CD40 and CD11c on
immature DCs that had been cultured with CD4CD25CD40, and I-Ag7 (Figure 5C). In contrast, DCs cultured
alone or in the presence of CD4CD25 cells expressed cells (Figure 5D, right panels). We therefore conclude
that NOD- and NOD.CD154/-derived CD4CD25 cellssignificantly higher levels of all these markers (Figure
5C). In agreement with these results, DCs cultured with inhibit 8.3-CD8 responses indirectly, by suppressing
DC maturation.CD4CD25 cells were significantly less efficient at elic-
iting IFN- secretion by 8.3-CD8 cells than DCs cultured
alone (about half; data not shown). Thus, CD4CD25cells CpG DNA Prevents the Induction of APC
Unresponsiveness by CD154/CD4 Cellscan inhibit the maturation process that bone marrow-
derived DCs normally undergo when replated in the ab- The in vivo and in vitro results described above indicated
that CD154 blockade abrogates the Th function ofsence of GM-CSF and/or IL-4 (Lutz et al., 1999).
To investigate whether CD4CD25 cells can also in- CD4CD25 cells without impairing the suppressive ac-
tivity of CD4CD25 cells against immature DCs. Thehibit mature DCs, we repeated the experiments above
but using LPS- or CpG DNA-activated DCs. The pheno- data also suggested that activation of DCs renders them
DCs as Targets of Regulatory T Cells
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Figure 5. NOD and NOD.CD154/ CD4CD25 Cells Downregulate DC Function In Vitro and Inhibit 8.3-CD8 Cells Indirectly via DCs
(A) Activated CD4CD25 cells (2  105) from NOD and NOD.CD154/ mice (8- to 15-week-old) cannot inhibit 8.3-CD8 responses (2  104)
induced by NRP-A7/Kd or IGRP206-214/Kd monomers. Monomers could not elicit IFN- secretion by CD4CD25 cells (not shown).
(B) Immature bone marrow-derived DCs cultured with NOD CD4CD25 cells express lower levels of several DC markers as compared to
DCs cultured with NOD CD4CD25 cells.
(C) Splenic CD4CD25 cells from NOD.CD154/ mice inhibit the upregulation of markers on immature bone marrow-derived DCs. CD11c
DCs were phenotyped after a 7 day culture with GM-CSF and IL-4, or cultured alone or in the presence of activated CD4CD25 or CD4CD25
cells (at 1:1 ratio) for 56 hr.
(D) Splenic CD4CD25 cells inhibit DC maturation. Left and middle panels: bone marrow-derived DCs were activated with CpG DNA or LPS,
washed, cultured with activated NOD CD4CD25 cells as in (B), and analyzed by FACS. Panels show levels of CD11c and CD40 on CD11c
cells. Right panels: immature DCs were cultured with activated NOD CD4CD25 cells, stimulated with CpG DNA, and analyzed. Histograms
correspond to live CD4 cells.
(E) Splenic CD4CD25 cells cannot inhibit the APC activity of CpG- or LPS-activated DCs.
refractory to CD4CD25-induced suppression. To test the infusion of total CD154/ CD4 cells. Strikingly, 90%
of the CpG-treated 8.3-NOD.RAG-2//CD154/ hoststhe validity of this idea in vivo, we investigated whether
systemic activation APCs could inhibit the antidiabeto- developed diabetes within 8 days after cell transfer (as
compared to only 18% of the non-CpG DNA-treatedgenic activity of CD154/ CD4CD25 cells. We first
monitored the incidence of diabetes in 8.3-NOD.RAG- controls; Table 1, Groups 12 versus 6 and 13). Diabetes
in these mice was caused by 8.3-CD8 cells, as2//CD154/and NOD.RAG-2//CD154/ mice that re-
ceived CpG or non-CpG DNA treatment 1 day prior to NOD.RAG-2//CD154/ mice treated the same way re-
Immunity
886
Figure 6. NOD CD4CD25 Cells Inhibit DC-Induced Activation of 8.3-CD8 Cells in a CTLA-4-Dependent, but IL-4-, IL-10-, and TGF-1-
Independent Manner
CD4CD25 cells from NOD (A and B) or NOD.IL4/ and NOD.IL-10/ mice (C) (10- to 16-week-old) were cocultured with NRP-A7-pulsed
DCs and 8.3-CD8 cells in the presence or absence of blocking or control Abs. For TGF-1, similar results were obtained with anti-human
TGF-1 chicken antiserum and the mAb 2G7 (data shown correspond to 2G7).
mained disease free (Table 1, Groups 16 and 17). To further are not the target of their regulatory activity (Thornton
and Shevach, 1998). Our data not only argue againstsubstantiate these results, we transfused CD154/CD4
CD25 cells into 8.3-NOD.RAG-2//CD154/ hosts that a passive role for APCs in the regulatory function of
CD4CD25 cells in vivo, but also show that the balancehad been treated with one injection of an agonistic anti-
CD40 mAb. The incidence of diabetes in these mice was between regulatory and Th cells can be controlled by
CD40-CD154 interactions. Thus, we have shown thatcomparable to that seen in mice treated with the mAb
alone (Table 1, Groups 15 versus 14). Thus, APC activa- CD4CD25 cells dominantly suppress DC maturation
and the ability of DCs to induce diabetogenic CD8T celltion not only uncouples 8.3-CD8 T cell activation from
the need for CD154 on CD4 Th cells, but also blocks responses if CD4CD25 Th cells lack CD154. Since
LPS-, CpG DNA-, and anti-CD40 mAb-activated DCs arethe antidiabetogenic activity of CD4CD25 cells.
refractory to the regulatory activity of CD4CD25 cells,
we conclude that ligation of CD40 on DCs by CD154 onThe Regulatory Activity of CD154/ CD4 CD25 Cells
Is CTLA-4 Dependent but IL-4 and IL-10 Independent Th cells releases DCs from the control of CD4CD25
cells. Another important corollary of this work is thatWe next investigated the mechanisms by which
CD154/ CD4CD25 cells suppressed 8.3-CD8 re- development of CD4CD25 cells in NOD mice is
CD154 independent.sponses. Blocking anti-IL-4, anti-IL-10, and anti-TGF-
1 antibodies were unable to inhibit these regulatory cells DCs were major targets of the suppressive activity of
NOD CD4CD25 cells. This is largely demonstrated byin vitro (Figures 6A and 6B). Furthermore, CD4CD25
cells isolated from IL-4 and IL-10-deficient NOD mice the finding that DCs, but not 8.3-CD8 cells, from 8.3-
NOD.RAG-2/CD154/ mice were functionally and phe-inhibited 8.3-CD8 responses equally well (Figure 6C).
Anti-CTLA-4 mAb, on the other hand, almost completely notypically abnormal. Since the above abnormalities
were not seen in DCs isolated from PLNs of mice that doabrogated the suppressive activity of these regulatory
cells in vitro (Figure 6A). All these results were confirmed not develop islet inflammation (B10.H2g7), we reasoned
they did not reflect the absence of a local immune re-in vivo. Introduction of an IL-10 deficiency into 8.3-NOD.
RAG-2/CD154/ mice was unable to restore the diabe- sponse. In addition, since these abnormalities were also
absent in the splenic DCs of T cell-deficient NOD.scidtogenic activity of 8.3-CD8 cells (only 1 of 24 mice
followed for 32 weeks became diabetic). Studies with mice, they could not be accounted for by absence of
T cell-induced DC maturation (in NOD.CD154/ mice).nine IL-4-deficient 8.3-NOD.RAG-2/CD154/ mice fol-
lowed for at least 25 weeks have yielded similar results The fact that NOD.scid DCs displayed a more mature
phenotype than NOD.CD154/ DCs was not unex-(no diabetic mice; data not shown). Anti-CTLA-4 mAb in-
jections, on the other hand, abrogated the antidiabeto- pected. In the absence of CD4CD25 cells (in NOD.scid
mice), environmental innate stimuli borne by specificgenic activity of CD154/ CD4CD25 cells upon adop-
tive transfer into 8.3-NOD.RAG-2/ mice (Table 1, pathogen-free mice, such as bacterial products derived
from the gut flora, might be able to induce a certainGroups 10 and 8).
degree of DC maturation.
In short-term cultures, CD4CD25 cells from NODDiscussion
and NOD.CD154/ mice downregulated the expression
of markers on DCs, and inhibited their ability to elicitSince CD4CD25cells can suppress APC-independent
T cell responses in vitro, it has been proposed that APCs 8.3-CD8 T cell responses in vitro. The relatively small
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effects that regulatory cells had on DCs in these short- bility is that ligation of CTLA-4 elicits the production
term in vitro assays are consistent with the idea that of cytokines capable of downregulating costimulatory
these T cells suppress 8.3-CD8 responses by inhibiting activity of DCs (Annacker et al., 2001; Annunziato et al.,
the maturation of DCs, rather than by inactivating them. 2002; Cederbom et al., 2000; Chen et al., 1998; Naka-
Four lines of evidence support this contention. First, mura et al., 2001; Read et al., 2000; Roncarolo and Lev-
whereas replating of immature DCs results in DC matu- ings, 2000). Nevertheless, mAb blocking experiments
ration and upregulation of DC markers (Lutz et al., 1999) and studies with cytokine-deficient regulatory cells have
(also see Figure 5C), CD4CD25 cells inhibited this shown that the inhibitory activity of NOD CD4CD25
process. Second, activation of immature DCs with CpG cells against 8.3-CD8 responses is not mediated by
DNA or LPS abrogated the ability of CD4CD25 cells IL-4, IL-10, or TGF-1.
to downregulate DC markers, or to inhibit 8.3-CD8 re- In closing, our data have shown that NOD regulatory
sponses in vitro. Third, systemic activation of DCs with T cells dominantly suppress DC maturation in vivo in
CpG DNA or an agonistic anti-CD40 mAb completely the absence of CD154 CD4CD25 Th cells. This pre-
inhibited the antidiabetogenic activity of CD4CD25 viously unrecognized function of regulatory cells may
cells in vivo. And fourth, CpG DNA could neither upregu- have evolved as a mechanism to prevent the nonspecific
late DC markers in the presence of CD4CD25 cells activation of effector T cells by low-affinity ligands of
nor elicit in vivo activation of ignorant 8.3-CD8 cells their TCRs, and may be controlled by CTLA-4-B7 inter-
in 8.3-NOD.RAG-2/CD154/ mice. Collectively, these actions. Since the affinity of CTLA-4 for B7 is much
observations suggest that, in steady state conditions, higher than that of CD28, and since CTLA-4 signaling
CD4CD25 cells may serve to keep DCs in the off activates T-regulatory cells in vivo (Read et al., 2000;
mode, and that susceptibility of DCs to “suppression” Salomon et al., 2000; Takahashi et al., 2000), these regu-
is a function of their activation state. These observations latory cells may help keep immature DCs in the off mode.
may explain why CD154/ CD4 cells cannot signifi- Constitutive expression of low levels of CD154 on naive
cantly inhibit the transfer of diabetes to NOD.scid mice Th cells (below the threshold of detection by cytometry)
by total NOD splenocytes (Eshima et al., 2003). In this may suffice to partially counteract the DC-inhibitory ac-
study, manifestation of the regulatory activity of CD154/ tivity of CD4CD25 cells, allowing a certain degree of
CD4 cells might have been inhibited by NOD CD154 responsiveness to DC stimuli. In this case (but not in
CD4 splenocytes (i.e., by inducing DC activation). the absence of Th cells), antigen-activated Th cells and/
Although immature DCs can be tolerogenic in vivo or innate stimuli from the environment would be able
(Dhodapkar et al., 2001), they appear to maintain T cell to fully release immature DCs from suppression. This
ignorance, rather than induce tolerance, in our model. hypothesis would help explain why signals capable of
This is suggested by three observations. First, whereas activating APCs, such as CpG DNA (via TLR9), anti-
regional tolerance of autoreactive CD8 cells in another CD40 ligation, or high-avidity CD4 Th cells (via CD40),
model has been associated with proliferation (Kurts et can release DCs from this regulatory activity, licensing
al., 1997), 8.3-CD8 cells failed to proliferate in the PLNs them to promote productive CD4 and CD8 responses.
of NOD.CD154/ hosts, which contain phenotypically Accordingly, CD154 blockade would blunt immune re-
immature DCs as compared to the PLNs of NOD mice. sponses not only by preventing T-T collaboration, but
Second, treatment of 8.3-NOD.RAG-2/ mice with CpG also by favoring the dominant suppressive activity that
DNA or agonistic anti-CD40 mAb blocked the antidiabe- CD4CD25cells have on DCs in a helper-deficient envi-
togenic effect of unfractionated CD154/ CD4 cells. ronment.
And third, CpG DNA treatment restored the ability
of “ignorant” 8.3-CD8 cells from 8.3-NOD.RAG-2/ Experimental Procedures
CD154/ mice to be activated upon infusion of CD154
MiceCD4 Th cells.
8.3-NOD and 8.3-NOD.RAG-2/ mice have been described (Verda-This proposed role of DCs as targets of CD4CD25
guer et al., 1997). NOD.scid and C57BL/6 mice were from the Jack-cells is further supported by observations indicating that
son Lab (Bar Harbor, ME). RIP-B7.1-NOD.scid, LCMV-TCR-trans-8.3-CD8 cells are refractory to direct inhibition by regu- genic NOD, NOD.IL-10/, and NOD.IL-4/ mice were provided by
latory cells. Thus, CD4CD25 cells could not downreg- D. Serreze (The Jackson Lab). C57BL/10.H2g7 (B10.H2g7) mice were
ulate 8.3-CD8 responses induced by peptide/MHC mo- from L. Wicker (Merck Research Laboratories, Rahway, NJ).
nomers, or by CpG/LPS-activated DCs. This resistance NOD.CD154/ mice have been described (Amrani et al., 2002). All
mice were produced by intercrossing heterozygous mutant, trans-of 8.3-CD8 cells to direct inhibition by regulatory cells
genic mice, and were housed in SPF conditions.may be a unique property of 8.3-CD8 cells or of CD8
cells selected on NOD MHC class I molecules, because
Diabetes
the presence of APCs is dispensable in other systems Diabetes was monitored by measuring urine glucose with Diastix
(Piccirillo and Shevach, 2001; Thornton and Shevach, (Miles, Ontario, Canada). Animals were considered diabetic after
1998). Nevertheless, this phenomenon is not a peculiar- two readings 3.
ity of NOD regulatory T cells, because it also occurs
Cell Lines and Antibodieswith regulatory cells derived from B10.H2g7 mice (unpub-
All mAbs were from PharMingen (San Diego, CA), unless indicatedlished data).
otherwise. The FGK45 (anti-CD40) hybridoma was from A. RolinkAs in other models (Annunziato et al., 2002; Read
(Basel Institute for Immunology, Basel, Switzerland). The 9H10 (anti-
et al., 2000; Takahashi et al., 2000), CTLA-4 blockade CTLA-4) hybridoma was from C. Chambers and J. Allison (Universi-
abrogated the inhibitory activity of CD154/ CD4CD25 ties of Massachusetts and California at Berkeley, respectively). The
cells against 8.3-CD8 responses. The mechanisms of 2G7 (anti-TGF-1) hybridoma was from L. Chatenoud (Hospital
Necker, Paris). Blocking anti-IL-4 and anti-IL-10 mAbs were fromaction of CTLA-4 in our system are unknown. One possi-
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R&D Systems (Minneapolis, MN). Control mAbs for blocking experi- vation of CD4CD25 and CD4CD25 cells involved a 2 day culture
on anti-CD3-coated (1 	g/ml) wells in the presence of rIL-2. Somements were irrelevant isotype-matched Abs (hamster anti-KLH Ab
for 9H10; and rat anti-B220 mAb for 2G7). Biotinylated anti-human experiments involved activating freshly isolated CD4CD25 cells
within the assay (see legend to Supplemental Figure S4 at http://TGF-1 chicken IgY and anti-mouse GITR goat IgG were from
R& D Systems. Biotinylated chicken IgY and FITC-labeled donkey www.immunity.org).
anti-goat IgG were from Jackson Immunoresearch (West Grove,
PA). Mouse IgG-absorbed-FITC or goat anti-rat IgG-biotin, and goat Studies of DCs Cultured in the Presence of CD4CD25 T Cells
anti-mouse IgG-FITC and Streptavidin-PerCP were from Caltag (San The ability of CD4CD25 cells to inhibit DC maturation in vitro
Francisco, CA) and Becton-Dickinson (San Jose, CA), respectively. was assessed in three different ways. One involved coculturing 106
immature bone marrow-derived DCs with 106 anti-CD3-activated
Peptides and Peptide/MHC Monomers T cells for 56 hr without rIL-2. A second strategy involved culturing
Peptides and monomers were produced as described (Amrani et 3  106 immature DCs with an equal number of preactivated
al., 2000; Lieberman et al., 2003). CD4CD25 cells for 48 hr, followed by an overnight culture in the
presence of CpG DNA (10 nmoles/dish). Live CD4/CD11c cells
were analyzed by flow cytometry for expression of DC markers. AGeneration of 8.3-CD8 CTL and 51Cr-Release Assays
third strategy involved overnight activation of DCs with LPS or CpG8.3-CD8 splenocytes were purified with anti-CD8-coated beads
ODN, followed by purification of DCs with anti-CD11c-coated beads(Miltenyi Biotec, Auburn, CA), adjusted to 2  104 cells/well, stimu-
and a 48 hr culture with an equal number of preactivatedlated with NRP-A7-pulsed (0.0001 to 1 	M) DCs (5  103) for 3 to
CD4CD25 T cells (3  106). The ability of CD4CD25 cells to4 days, and expanded in 0.5 U/ml of rIL-2 (Takeda, Osaka, Japan)
induce DC hypo-function was assessed by depleting CD4 cells orfor 7–10 days. 51Cr-release assays were done as described, at a
by purifying DCs from the DC/CD4CD25 cocultures (with beads),1:10 target:effector ratio (Verdaguer et al., 1997).
and by measuring their ability to present peptides to 8.3-CD8 cells.
In these experiments, DCs were pulsed with 1 	M peptide, washed,Preparation of DCs
and cultured (1–2  104) with 2  104 8.3-CD8 cells. Alternatively,Bone marrow-derived DCs were prepared by culturing marrow cells
LPS or CpG ODN-activated DCs were purified with anti-CD11c-in rmGM-CSF and rmIL4 (5 ng/ml) for 7 days, followed by purification
coated beads, pulsed with peptides, washed, and incubated (104)with anti-CD11c-coated beads (Miltenyi Biotec). Unless indicated
with 2  104 8.3-CD8 cells and 105 preactivated CD4CD25 cells.otherwise, all DCs were used as immature cells. In some experi-
ments, purified DCs were stimulated overnight with LPS (Sigma, St.
Louis, MO; 2.5 	g/ml) or CpG oligodeoxynucleotide (ODN; MWG MAb and CpG ODN Treatment
Biotech, Charlotte, NC; 10 nmoles/dish) (Hemmi et al., 2000). Periph- Mice received one injection of 100 	g of anti-CD40 mAb (FGK45)
eral DCs were purified from collagenase digested spleens (n 5–10), i.p. 1 day before transfer of CD4CD25 cells, or three injections of
and MLN or PLNs (n 6-30) using anti-CD11c-coated beads. Purity 100 	g of mAb 3–4 days apart without CD4CD25 cells. Alterna-
was 95% CD11c cells. tively, mice received 3 doses of 50 	g anti-CTLA-4 mAb (9H10; i.v.)
with or without CD4CD25 cells, and once a week i.p. for two
additional weeks. Other mice were treated with one i.p injection ofT Cell/DC Transfers
phosphorothioate-stabilized CpG and non-CpG ODNs (10 nmoles)Splenic CD8 cells (107) were labeled with CFSE and transfused into
(Hemmi et al., 2000), the day before T cell transfer.8- to 10-week-old hosts. Hosts were sacrificed 6 days later and
their PLN and MLN examined for presence of CFSE cells. To trans-
fer CD4 cells, splenocytes from 8- to 15-week-old mice were de- Histopathology
pleted of CD8 cells and B cells, or subjected to positive selection Pancreata were fixed in formalin, embedded in paraffin, sectioned
with anti-CD4 mAb-coated beads. To purify CD4CD25 and at 4.5 	M, stained with hematoxylin and eosin, and examined for
CD4CD25 cells, lymph node and/or splenic cells were depleted insulitis as described (Verdaguer et al., 1997).
of CD8 and B cells, incubated with anti-CD25-PE, and separated
using anti-PE mAb-coated beads (Milteny Biotec). The purity Statistical Analyses
was 90% for CD4CD25 and 80% for CD4CD25 cells. The Data were compared by Mann-Whitney U test or 2.
cells (1.5 107 CD4; 2–4 106 CD4CD25; or 1 107 CD4CD25)
were injected i.v. The mice were followed for at least 10 weeks
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